AP39 through AMPK-ULK1-FUNDC1 pathway regulates mitophagy inhibits pyroptosis improves doxorubicin-induced myocardial fibrosis

Junxiong Zhao,Ting Yang,Jiali Yi,Hongmin Hu,Qi Lai,Liangui Nie,Maojun Liu,Chun Chu,Jun Yang
DOI: https://doi.org/10.1016/j.isci.2024.109321
IF: 5.8
2024-02-01
iScience
Abstract:Doxorubicin inducing myocardial injury and fibrosis. Still, no effective interventions are available. AP39 is an H2S donor that explicitly targets mitochondria. This study investigated whether AP39 could improve doxorubicin-induced myocardial fibrosis. Doxorubicin-induced significant myocardial fibrosis while suppressing mitophagy-related proteins and elevating pyroptosis-related proteins. Conversely, AP39 reverses these effects, enhancing mitophagy and inhibiting pyroptosis. In vitro experiments revealed that AP39 inhibited H9c2 cardiomyocyte pyroptosis, improved doxorubicin-induced impairment of mitophagy, reduced ROS levels, ameliorated the mitochondrial membrane potential, and upregulated AMPK–ULK1–FUNDC1 expression. In contrast, AMPK inhibitor(dorsomorphin) and ULK1 inhibitor(SBI-0206965) reversed AP39 antagonism of doxorubicin-induced FUNDC1-mediated impairment of mitophagy and secondary cardiomyocyte pyroptosis. These results suggest that mitochondria-targeted H2S can antagonize doxorubicin-induced pyroptosis and impaired mitophagy in cardiomyocytes via AMPK–ULK1–FUNDC1 and ameliorated myocardial fibrosis and remodeling.
multidisciplinary sciences
What problem does this paper attempt to address?